Edge Therapeutics, Inc, a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage. The company is also developing EG-1964, as a prophylactic treatment for the management of chronic subdural hematoma to prevent recurrent bleeding on the surface of the brain; and EG-1965, for the prevention of post-operative atrial fibrillation.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone800-208-3343
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
Edge Therapeutics (NASDAQ:EDGE) Frequently Asked Questions
What is Edge Therapeutics' stock symbol?
Edge Therapeutics trades on the NASDAQ under the ticker symbol "EDGE."
How were Edge Therapeutics' earnings last quarter?
Edge Therapeutics Inc (NASDAQ:EDGE) released its quarterly earnings results on Thursday, November, 1st. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.16. View Edge Therapeutics' Earnings History.
Has Edge Therapeutics been receiving favorable news coverage?
News coverage about EDGE stock has trended positive on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Edge Therapeutics earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the next several days. View News Stories for Edge Therapeutics.
Who are some of Edge Therapeutics' key competitors?
Some companies that are related to Edge Therapeutics include Unum Therapeutics (UMRX), China SXT Pharmaceuticals (SXTC), SCYNEXIS (SCYX), NewLink Genetics (NLNK), VBI Vaccines (VBIV), Marinus Pharmaceuticals (MRNS), VERONA PHARMA P/S (VRNA), Ophthotech (OPHT), Pharmaxis (PXSLY), IMMUTEP LTD/S (IMMP), Oramed Pharmaceuticals (ORMP), Hoth Therapeutics (HOTH), Moleculin Biotech (MBRX), Eyenovia (EYEN) and PLx Pharma (PLXP).
What other stocks do shareholders of Edge Therapeutics own?
Who are Edge Therapeutics' key executives?
Edge Therapeutics' management team includes the folowing people:
- Mr. Brian A. Leuthner, Co-Founder, CEO, Pres & Director (Age 54)
- Dr. R. Loch MacDonald, Co-Founder, Chief Scientific Officer & Director (Age 57)
- Mr. Andrew Saik, Chief Financial Officer (Age 50)
- Mr. W. Bradford Middlekauff, Sr. VP, Gen. Counsel & Sec. (Age 57)
- Mr. William Shatynski, Sr. Director of Financial Reporting & Controller
How do I buy shares of Edge Therapeutics?
Shares of EDGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Edge Therapeutics' stock price today?
One share of EDGE stock can currently be purchased for approximately $0.5036.
How big of a company is Edge Therapeutics?
What is Edge Therapeutics' official website?
How can I contact Edge Therapeutics?
Edge Therapeutics' mailing address is 300 Connell Drive Suite 4000, Berkeley Heights NJ, 07922. The biotechnology company can be reached via phone at 800-208-3343 or via email at [email protected]
MarketBeat Community Rating for Edge Therapeutics (NASDAQ EDGE)
MarketBeat's community ratings are surveys of what our community members think about Edge Therapeutics and other stocks. Vote "Outperform" if you believe EDGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDGE will underperform the S&P 500 over the long term. You may vote once every thirty days.
